49.84 USD
+0.26 (+0.52%)
49.84 USD
0 (0%)
Taking everything into account, COLL scores 6 out of 10 in our fundamental rating. COLL was compared to 192 industry peers in the Pharmaceuticals industry. COLL scores excellent on profitability, but there are some minor concerns on its financial health. COLL may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make COLL suitable for value investing!
1. Profitability
1.1 Basic Checks
COLL had positive earnings in the past year.
In the past year COLL had a positive cash flow from operations.
COLL had positive earnings in 4 of the past 5 years.
In the past 5 years COLL always reported a positive cash flow from operatings.
1.2 Ratios
COLL has a Return On Assets of 3.64%. This is amongst the best in the industry. COLL outperforms 83.85% of its industry peers.
COLL has a better Return On Equity (21.27%) than 91.15% of its industry peers.
COLL's Return On Invested Capital of 9.10% is amongst the best of the industry. COLL outperforms 88.02% of its industry peers.
COLL had an Average Return On Invested Capital over the past 3 years of 11.08%. This is in line with the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
COLL's Profit Margin of 7.72% is amongst the best of the industry. COLL outperforms 82.81% of its industry peers.
COLL's Profit Margin has declined in the last couple of years.
COLL has a Operating Margin of 20.74%. This is amongst the best in the industry. COLL outperforms 88.54% of its industry peers.
COLL's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 57.22%, COLL is doing good in the industry, outperforming 67.71% of the companies in the same industry.
COLL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
COLL has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, COLL has less shares outstanding
Compared to 1 year ago, COLL has an improved debt to assets ratio.
2.2 Solvency
COLL has an Altman-Z score of 1.52. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
COLL's Altman-Z score of 1.52 is in line compared to the rest of the industry. COLL outperforms 54.69% of its industry peers.
The Debt to FCF ratio of COLL is 2.79, which is a good value as it means it would take COLL, 2.79 years of fcf income to pay off all of its debts.
COLL's Debt to FCF ratio of 2.79 is amongst the best of the industry. COLL outperforms 90.63% of its industry peers.
A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
COLL's Debt to Equity ratio of 2.71 is on the low side compared to the rest of the industry. COLL is outperformed by 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.52 |
ROIC/WACC0.98
WACC9.25%
2.3 Liquidity
COLL has a Current Ratio of 1.36. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
COLL's Current ratio of 1.36 is on the low side compared to the rest of the industry. COLL is outperformed by 73.96% of its industry peers.
A Quick Ratio of 1.27 indicates that COLL should not have too much problems paying its short term obligations.
COLL has a worse Quick ratio (1.27) than 70.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.73%, which is quite impressive.
COLL shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 154.78% yearly.
Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 26.34%.
COLL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.31% yearly.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
COLL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.58% yearly.
The Revenue is expected to grow by 3.62% on average over the next years.
EPS Next Y19.18%
EPS Next 2Y12.57%
EPS Next 3Y-4.69%
EPS Next 5Y-1.58%
Revenue Next Year24.31%
Revenue Next 2Y13.52%
Revenue Next 3Y2.59%
Revenue Next 5Y3.62%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 6.93, which indicates a rather cheap valuation of COLL.
COLL's Price/Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 94.79% of the companies in the same industry.
COLL is valuated cheaply when we compare the Price/Earnings ratio to 26.57, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 6.10, the valuation of COLL can be described as very cheap.
Based on the Price/Forward Earnings ratio, COLL is valued cheaply inside the industry as 95.31% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, COLL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.93 | ||
| Fwd PE | 6.1 |
4.2 Price Multiples
COLL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. COLL is cheaper than 97.92% of the companies in the same industry.
COLL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. COLL is cheaper than 96.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.45 | ||
| EV/EBITDA | 5.1 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of COLL may justify a higher PE ratio.
A cheap valuation may be justified as COLL's earnings are expected to decrease with -4.69% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y12.57%
EPS Next 3Y-4.69%
5. Dividend
5.1 Amount
No dividends for COLL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
49.84
+0.26 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners120.37%
Inst Owner Change0.64%
Ins Owners1.43%
Ins Owner Change-0.82%
Market Cap1.58B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.82
Price Target49.64 (-0.4%)
Short Float %18.91%
Short Ratio11.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)9.12%
PT rev (3m)9.12%
EPS NQ rev (1m)-0.33%
EPS NQ rev (3m)7.88%
EPS NY rev (1m)-15.27%
EPS NY rev (3m)-8.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.69%
Revenue NY rev (1m)4.07%
Revenue NY rev (3m)3.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.93 | ||
| Fwd PE | 6.1 | ||
| P/S | 2.08 | ||
| P/FCF | 5.45 | ||
| P/OCF | 5.42 | ||
| P/B | 5.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.1 |
EPS(TTM)7.19
EY14.43%
EPS(NY)8.17
Fwd EY16.4%
FCF(TTM)9.15
FCFY18.36%
OCF(TTM)9.2
OCFY18.47%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.36
PEG (5Y)N/A
Graham Number37.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.52 |
F-Score7
WACC9.25%
ROIC/WACC0.98
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y19.18%
EPS Next 2Y12.57%
EPS Next 3Y-4.69%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year24.31%
Revenue Next 2Y13.52%
Revenue Next 3Y2.59%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year154.57%
EBIT Next 3Y23.61%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.